100% Success of Anti-Alzheimer’s Protocol For Early Stages of The Disease
While drugs against Alzheimer’s are ineffective, attention is focused on Dr Dale Bredesen’s ReCODE protocol, touted as the first program to reverse Alzheimer’s disease.
Dr. Dale Bredesen is a neurologist and has spent more than 30 years researching neurodegenerative diseases, which has allowed him and his team to develop a treatment protocol that reverses the symptoms (provided they ‘to be continued for life). In The End of Alzheimer’s, a bestseller across the Atlantic, he explains the new light that his research has given to Alzheimer’s disease, its causes and its treatments.
You are at the origin of a research laboratory on neurodegenerative diseases at the University of California. What guided your work?
Dr. Dale Bredesen : When I started studying neurology, most brain diseases were incurable, whether it was stroke, Parkinson’s or Alzheimer’s, lateral sclerosis amyotrophic (ALS) or many other diseases, all intractable. I made the decision thirty years ago to create a research laboratory. The goal of our laboratory has always been to understand the fundamental nature of the degenerative process in sufficient detail to be able to establish the first effective treatments and preventive advice against these diseases.
What did you find about Alzheimer’s?
After many years of studying Alzheimer’s disease in different laboratory models, we came to an astonishing conclusion: Alzheimer’s disease is fundamentally different from the commonly accepted model. Its underlying mechanism does not correspond to the production of amyloid plaques, but to a change of equilibrium between the synaptoclastic signals (responsible for destroying the neurons) and the synaptoblastic signals (responsible for repairing and renewing the neurons). In other words, in Alzheimer’s disease, there are too many synaptoclastic signals and not enough synaptoblastics.
What do these amyloid plaques, which are found in numbers in the brains of Alzheimer’s patients, correspond to?
The production of amyloid plaques seen in patients is actually part of the protective response of the brain against phenomena that unbalance these signals:
First, inflammation of the brain due to bacteria and fungi in the mouth, to spirochaete bacteria found in Lyme disease and co-infections.
Second, the decline of certain nutrients and hormones with age (testosterone, progesterone, pregnenolone …).
And thirdly, exposure to different toxins.
Does this mean that we are doing the wrong thing by trying, with medication, to reduce these amyloid plaques?
Indeed. We realized that instead of trying to blindly treat these amyloid plaques, without knowing what they are due, as is the case of current treatments for Alzheimer’s disease, which do not work, it had to tackle its real causes. And we published the first case examples of improvement of Alzheimer’s and pre-Alzheimer’s patients in 2014. And since then I have seen more and more patients and I realized that I could not put in a scientific publication all that was needed to understand the disease and the results obtained with the protocol developed with my team. That’s why I decided to write a book, The End of Alzheimer’s, about these patients, about the mechanisms that cause Alzheimer’s and how to prevent and reverse the symptoms.
We basically had three types of reaction:
- Skeptical people.
- People who said “I do not believe it” without even looking at our data or asking to meet our patients while we have with our protocol ReCODE improvements that are very well documented and for a significant number of patients.
- Some people who said, “I’m waiting for published long-term trials.” And it’s a pretty ethical reaction, I agree with that. Besides, we are currently working on a test, and we will see its results.
But the important thing for me is that when you suffer from a lethal and incurable disease with the current drugs, you have to start somewhere. And if someone offers a treatment that seems to work in different people, it seems logical to want to try it. So, yes, there is still a lot to be done, it is a beginning, a treatment that is not effective for everyone, especially for those who are at advanced stages of the disease. We still have to understand why some people, even with advanced Alzheimer’s, respond well to treatment and others, no.
The study published in 2016 in Aging concerned only 10 patients. How many people are participating in your current trial?
We have an essay on 50 people scheduled to be published in 2019. What is remarkable is that the 50 patients have all seen their condition improve, regardless of the stage of their disease. We are also working on a study of 2000 people currently. We have trained more than 1000 doctors from ten countries who use the ReCODE protocol. Five of them, who do not belong to our laboratory, are involved in this new trial and obtain similar results.
How many people have followed your protocol to date and what is its success rate?
In 6 years of use of this protocol, more than 2000 people have followed our treatment. For patients whose disease is just declared or not advanced, the symptoms are reversing for sure, with a success close to 100%. For more advanced stages, it is more difficult. On average, the success rate in terms of inversion of symptoms is greater than 50%.
Your protocol involves many dietary and lifestyle changes. Can not this put off some patients, relatives, their doctors?
Once again, we have to start somewhere. I remember the first computers: they were huge, heavy and very expensive. Look how in 30-40 years they have become smaller and more accessible to the greatest number. I bet that with the protocol ReCODE it will be the same thing. We start with something complicated but this treatment will be simplified as we will refine our knowledge and perhaps one day its main rules will be an integral part of everyone’s daily life.
Let’s talk about nutrition. What dietary changes are the most protective against Alzheimer’s disease and at what age should we adopt them?
The best diet against Alzheimer’s is based on plants, with whole foods little or not processed, from organic farming and without GMOs. What you eat should also be low in carbohydrates to induce mild ketosis. To promote this state of ketosis we propose what we called the cetoflex 12/3: 12 hours minimum without eating anything between the end of dinner and the next breakfast and 3 hours between the end of dinner and bedtime.
Eating mainly vegetables and inducing mild ketosis are two good habits to take.Our dietary recommendations are suitable for both vegetarians and omnivores. If you eat meat, you must choose it, preferably from grass fed animals. On the fish side, avoid those that come from a breeding and favor wild fish, less contaminated.
Starting to eat well, according to these precepts, at age 20 is a good idea. But obviously in your thirties or forties is good too.
How can I tell if I have a risk of Alzheimer’s?
There is a serious blood test that is described precisely in The End of Alzheimer’s. It includes genetics, biochemistry and microbiology. The first question to ask is: did anyone have Alzheimer’s disease in my family? Another important question: do I have insulin resistance (pre-diabetes)? In addition, if you have diabetes, it increases your risk. If you have intestinal problems, it also increases your risk. If you have a sedentary lifestyle and if you are or have been exposed to toxic substances from the environment, too.
All of these parameters can be measured in the blood and if you answer yes to a question above, you have every interest in doing a test. In my opinion, anyone over the age of 45 should check to see if they have a significant risk of Alzheimer’s disease or are already in the first stages of the disease. This disease is slowly developing and most people do not do anything until it is already a little late (or even late).
And among the risk factors you have just described, are there more important ones than others?
Certainly yes. In addition to the main factor of family history, the three most important risk factors correspond to the three types of Alzheimer’s disease that we identified with my team:
- Chronic inflammation, which predisposes to type 1 or inflammatory Alzheimer’s disease.
- Insulin resistance which can, with other factors, prefigure Alzheimer’s disease type 2, also called atrophic.
- Toxic exposure that induces at a young age type 3 Alzheimer’s disease, known as toxic, in genetically predisposed people.
What is the next step of your research?
Simplify the ReCODE protocol as I said, but also and especially tackle other neurodegenerative diseases, to better understand their mechanisms and establish treatments. We have already started, for example with Parkinson’s disease, with encouraging results.